<DOC>
	<DOC>NCT02045732</DOC>
	<brief_summary>PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Women and men aged 1855 yrs. Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2010 revision of the McDonald Criteria. Expanded Disability Status Scale (EDSS) between 05, inclusive. Relapse episode of MS within 2 weeks of enrollment. Primary progressive MS without a relapsing component. Intolerant or unwilling to undergo MRI scanning. Treatment with disease modifying agents up to 6 weeks prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MRI</keyword>
</DOC>